IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer

被引：2

作者：

Fujisawa, Toshio ^{[1
]}

Joshi, Bharat H. ^{[2
]}

Takahashi, Sho ^{[1
]}

Takasaki, Yusuke ^{[1
]}

Suzuki, Akinori ^{[1
]}

Ito, Koichi ^{[1
]}

Ochiai, Kazushige ^{[1
]}

Tomishima, Ko ^{[1
]}

Ishii, Shigeto ^{[1
]}

Puri, Raj K. ^{[2
]}

Isayama, Hiroyuki ^{[1
]}

机构：

[1] Juntendo Univ, Grad Sch Med, Dept Gastroenterol, Tokyo 1138421, Japan

[2] US FDA, Tumor Vaccines & Biotechnol Branch, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA

来源：

DIAGNOSTICS | 2021年 / 11卷 / 07期

关键词：

IL-13R alpha 2; cancer invasion; metastasis; pancreatic cancer; AP-1; pathway; INTERLEUKIN-13 RECEPTOR ALPHA-2; IL-13; RECEPTORS; POOR-PROGNOSIS; TARGET; METASTASIS; CHAIN; EXPRESSION; BINDING; GROWTH;

D O I：

10.3390/diagnostics11071140

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IL-13R alpha 2 is a high-affinity binding protein for its ligand IL-13 and a cancer-testis antigen as it is expressed in the testis. IL-13R alpha 2 is highly expressed in various cancers, including pancreatic cancer, and consists of three domains: extracellular, transmembrane, and cytoplasmic. The extracellular domain binds to the ligand to form a biologically active complex, which initiates signaling through AP-1 and other pathways. IL-13R alpha 2 is also expressed in diseased cells such as fibroblasts that are involved in various inflammatory diseases, including cancer. We have reported that IL-13R alpha 2 is a prognostic biomarker for malignant glioma, adrenocortical cancer, and pancreatic cancer. In pancreatic cancer, a small sample of tissue could be examined for the expression of IL-13R alpha 2 by using the endoscopic ultrasound-fine needle aspiration technique (EUS-FNA). In addition, a peptide-based targeted approach using Pep-1L peptide could be used to study the biodistribution and whole-body cancer imaging for the screening of pancreatic cancer in suspected subjects.

引用

页数：7

共 36 条

[21] Decoy receptors in the regulation of T helper cell type 2 responses [J].

McKenzie, ANJ ;

Fallon, PG .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :675-679

[22] INTERLEUKIN-13 IS A NEW HUMAN LYMPHOKINE REGULATING INFLAMMATORY AND IMMUNE-RESPONSES [J].

MINTY, A ;

CHALON, P ;

DEROCQ, JM ;

DUMONT, X ;

GUILLEMOT, JC ;

KAGHAD, M ;

LABIT, C ;

LEPLATOIS, P ;

LIAUZUN, P ;

MILOUX, B ;

MINTY, C ;

CASELLAS, P ;

LOISON, G ;

LUPKER, J ;

SHIRE, D ;

FERRARA, P ;

CAPUT, D .

NATURE, 1993, 362 (6417) :248-250

[23] Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme [J].

Newman, Jennifer P. ;

Wang, Grace Y. ;

Arima, Kazuhiko ;

Guan, Shou P. ;

Waters, Michael R. ;

Cavenee, Webster K. ;

Pan, Edward ;

Aliwarga, Edita ;

Chong, Siao T. ;

Kok, Catherine Y. L. ;

Endaya, Berwini B. ;

Habib, Amyn A. ;

Horibe, Tomohisa ;

Ng, Wai H. ;

Ho, Ivy A. W. ;

Hui, Kam M. ;

Kordula, Tomasz ;

Lam, Paula Y. P. .

NATURE COMMUNICATIONS, 2017, 8

[24] Modulation of interleukin (IL)-13 binding and signaling by the gamma(c) chain of the IL-2 receptor [J].

Obiri, NI ;

Murata, T ;

Debinski, W ;

Puri, RK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (32) :20251-20258

[25] Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma [J].

Okamoto, Hayato ;

Yoshimatsu, Yasuhiro ;

Tomizawa, Taishi ;

Kunita, Akiko ;

Takayama, Rina ;

Morikawa, Teppei ;

Komura, Daisuke ;

Takahashi, Kazuki ;

Oshima, Tsukasa ;

Sato, Moegi ;

Komai, Mao ;

Podyma-Inoue, Katarzyna A. ;

Uchida, Hiroaki ;

Hamada, Hirofumi ;

Fujiu, Katsuhito ;

Ishikawa, Shumpei ;

Fukayama, Masashi ;

Fukuhara, Takeshi ;

Watabe, Tetsuro .

SCIENTIFIC REPORTS, 2019, 9 (1)

[26] Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis [J].

Papageorgis, Panagiotis ;

Ozturk, Sait ;

Lambert, Arthur W. ;

Neophytou, Christiana M. ;

Tzatsos, Alexandros ;

Wong, Chen K. ;

Thiagalingam, Sam ;

Constantinou, Andreas I. .

BREAST CANCER RESEARCH, 2015, 17

[27] Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2 [J].

Popovic, B. ;

Breed, J. ;

Rees, D. G. ;

Gardener, M. J. ;

Vinall, L. M. K. ;

Kemp, B. ;

Spooner, J. ;

Keen, J. ;

Minter, R. ;

Uddin, F. ;

Colice, G. ;

Wilkinson, T. ;

Vaughan, T. ;

May, R. D. .

JOURNAL OF MOLECULAR BIOLOGY, 2017, 429 (02) :208-219

[28] A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer [J].

Raza, Ghulam ;

Yunus, Fakhar-un-Nisa ;

Mangukiya, Hitesh Bhagavanbhai ;

Merugu, Siva Bharath ;

Mashausi, Dhahiri Saidi ;

Wang Zeling ;

Negi, Hema ;

Zhou, Bingjie ;

Roy, Debmalya ;

Wu, Zhenghua ;

Li, Dawei .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 90

[29] Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker [J].

Sai, Kiran Kumar Solingapuram ;

Sattiraju, Anirudh ;

Almaguel, Frankis G. ;

Xuan, Ang ;

Rideout, Stephanie ;

Krishnaswamy, Rahul S. ;

Zhang, JoAnn ;

Herpai, Denise M. ;

Debinski, Waldemar ;

Mintz, Akiva .

ONCOTARGET, 2017, 8 (31) :50997-51007

[30] Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 Pseudomonas Exotoxin in Pancreatic Cancer Therapy [J].

Shimamura, Takeshi ;

Fujisawa, Toshio ;

Husain, Syed R. ;

Joshi, Bharat ;

Puri, Raj K. .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :577-586

← 1 2 3 4 →